ImmuPharma (LON:IMM) Trading Up 12.5% – Still a Buy?

ImmuPharma plc (LON:IMMGet Free Report)’s stock price shot up 12.5% during mid-day trading on Thursday . The company traded as high as GBX 5.80 ($0.07) and last traded at GBX 5.50 ($0.07). 19,527,068 shares traded hands during mid-day trading, a decline of 23% from the average session volume of 25,520,734 shares. The stock had previously closed at GBX 4.89 ($0.06).

ImmuPharma Stock Up 12.5 %

The firm has a market cap of £22.90 million, a P/E ratio of -550.00 and a beta of 1.53. The firm has a fifty day moving average of GBX 1.98 and a 200-day moving average of GBX 1.80.

About ImmuPharma

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Read More

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.